User talk:Minerviatta

Welcome!

Hello, Minerviatta, and welcome to Wikipedia! Thank you for your contributions. I hope you like the place and decide to stay. Here are a few links to pages you might find helpful:

• Introduction and Getting started
• Contributing to Wikipedia
• The five pillars of Wikipedia
• How to edit a page and How to develop articles
• How to create your first article
• Simplified Manual of Style

You may also want to take the Wikipedia Adventure, an interactive tour that will help you learn the basics of editing Wikipedia. You can visit The Teahouse to ask questions or seek help.

Please remember to sign your messages on talk pages by typing four tildes (~~~~); this will automatically insert your username and the date. If you need help, check out Wikipedia:Questions, ask me on my talk page, or ask for help on your talk page, and a volunteer should respond shortly. Again, welcome! Blythwood (talk) 05:47, 2 August 2017 (UTC)[reply]

Loncastuximab tesirine

Thanks for creating this article.

Could you please provide a reference establishing that ADCT-402 is loncastuximab tesirine? The current references refer to either the former or the latter, but not both.--pmj (talk) 23:30, 8 August 2017 (UTC)[reply]

The reference is established with the first reference mentioned in the article: "WHO Drug Information" on page 295 (or page 55 of the PDF) Minerviatta (talk) 20:14, 9 August 2017 (UTC)[reply]

I am not a biochemist and may have missed something that is obvious to experts. That PDF does describe loncastuximab tesirine, but has no mention of ADCT-402. The other references are vice versa. How do we establish that loncastuximab tesirine and ADCT-402 are the same thing?--pmj (talk) 04:15, 10 August 2017 (UTC)[reply]

You are right, there is no direct reference to both names in the article and without scientific knowledge it is not obvious. WHO published the proposed International Nonproprietary Name (pINN) only last month, that's why as far as I can see the name Loncastuximab teserine has not been used in any article or by the company. Minerviatta (talk) 12:13, 13 August 2017 (UTC)[reply]

Thanks for introducing me to INNs. Interesting process.

The connection between the two names in isolation would not seem to be obvious with any knowledge, unless it is established via e.g. a formula such as that in the pINN publication. Will you revise the article when more information becomes publicly available? I've created the ADCT-402 page as a redirect to Loncastuximab tesirine.--pmj (talk) 23:48, 13 August 2017 (UTC)[reply]

Sure, I will revise the article once I find a published article taking reference to both names. Minerviatta (talk) 12:30, 16 August 2017 (UTC)[reply]